From Partnership to Progress: The Estriol Expansion Story

In women’s health, reliability is everything. Since 2014, Transo-Pharm and the German manufacturer HAPILA GmbH have joined forces to ensure a stable and high-quality supply of Estriol – an essential hormone with global relevance.
 
When demand for micronized Estriol (CEP No.: R1-CEP 2013-277-Rev 00) increased, both companies made a bold move: to invest in the future. In 2019, we decided to expand capacity at HAPILA’s site in Gera, Germany. Just one year later, construction began on a new GMP-compliant facility – now fully operational.
 
The result: a stronger, more resilient supply chain that meets today’s needs and prepares for tomorrow’s.
 
Because innovation is more than new buildings and machines – it’s about partnerships that make reliable therapies possible.
 
📹 Watch the video and see how we build the future of Estriol supply, together.